COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1075-1085

  Shao, Jing ^a,b   Teng, Yong ^b   Padia, Ravi ^b   Hong, Sungguan ^b   Noh, Hyangsoon ^b   Xie, Xiayang ^b   Mumm, Jeff S ^b   Dong, Zheng ^b   Ding, Han Fei ^b   Cowell, John ^b   Kim, Jaejik ^b,c   Han, Jiahuai ^a   Huang, Shuang ^b,d  

^a XIAMEN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AUGUSTA UNIVERSITY   (United States)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEASOME; PROTEIN C JUN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE COP1; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RECURRENCE FREE SURVIVAL; ZEBRA FISH;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; ZEBRAFISH;

EID: 84884365703     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13966     Document Type: Article

References (35)

1. Karin M, Liu Z, and Zandi E (1997). AP-1 function and regulation. Curr Opin Cell Biol 9, 240-246.
2. Shaulian E and Karin M (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-E136.
3. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, and Birrer MJ (1999). cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18, 6063-6070.
4. Vleugel MM, Greijer AE, Bos R, van der Wall E, and van Diest PJ (2006). c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37, 668-674.
5. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, and Pestell RG (2010). c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285, 8218-8226.
6. Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M, et al. (2007). Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 7, 145.
7. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, and Brown PH (2008). The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 27, 366-377.
8. Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK, Liu K, and Huang S (2009). Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 69, 9228-9235.
9. Okutomi Y, Shino Y, Komoda F, Hirano T, Ishihara T, Yamaguchi T, Saisho H, and Shirasawa H (2003). Survival regulation in pancreatic cancer cells by c-Jun. Int J Oncol 23, 1127-1134.
10. Neyns B,Katesuwanasing, Vermeij J, Bourgain C, Vandamme B, Amfo K, Lissens W, DeSutter P, Hooghe-Peters E, and DeGrève J (1996). Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene 12, 1247-1257.
11. Tiniakos DG, Scott LE, Corbett IP, Piggott NH, and Horne CH (1994). Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J Pathol 172, 19-26.
12. Jariel-Encontre I, Salvat C, Steff AM, Pariat M, Acquaviva C, Furstoss O, and Piechaczyk M (1997). Complex mechanisms for c-fos and c-jun degradation. Mol Biol Rep 24, 51-56.
13. Westermarck J (2010). Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun. Methods Mol Biol 647, 31-36.
14. Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E, Zwolinska A, Depaepe V, Hochepied T, Skarnes WC, et al. (2011). Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest 121, 1329-1343.
15. Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, and Dixit VM (2004). Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 303, 1371-1374.
16. Nateri AS, Riera-Sans L, Da Costa C, and Behrens A (2004). The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303, 1374-1378.
17. Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, and Karin M (2004). Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306, 271-275.
18. Xia Y, Wang J, Xu S, Johnson GL, Hunter T, and Lu Z (2007). MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol 27, 510-517.
19. Gu Q, Bowden GT, Normolle D, and Sun Y (2007). SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IκB-α/NF-κB. J Cell Biol 178, 1009-1023.
20. Lin A, Frost J, Deng T, Smeal T, al-Alawi N, Kikkawa U, Hunter T, Brenner D, and Karin M (1992). Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity. Cell 70, 777-789.
21. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, and Davis RJ (1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-1037.
22. Wei W, Jin J, Schlisio S, Harper JW, and Kaelin WG Jr (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33.
23. Hong S, Noh H, Chen H, Padia R, Pan ZK, Su SB, Jing Q, Ding HF, and Huang S (2013). Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. Sci Signal 6, ra16.
24. Rouhi P, Jensen LD, Cao Z, Hosaka K, Lanne T, Wahlberg E, Steffensen JF, and Cao Y (2010). Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc 5, 1911-1918.
25. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447-460.
26. He H, Gu Q, Zheng M, Normolle D, and Sun Y (2008). SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 29, 858-865.
27. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, et al. (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67, 9472-9481.
28. Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu CX, et al. (2012). USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol 14, 717-726.
29. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, et al. (2012). ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 14, R148.
30. Gao B, Lee SM, and Fang D (2006). The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells. J Biol Chem 281, 29711-29718.
31. Zhang J, Zhu F, Li X, Dong Z, Xu Y, Peng C, Li S, Cho YY, Yao K, Zykova TA, et al. (2012). Rack1 protects N-terminal phosphorylated c-Jun from Fbw7-mediated degradation. Oncogene 31, 1835-1844.
32. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, and Tindall DJ (2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 102, 1649-1654.
33. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, and French DM (2004). COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 64, 7226-7230.
34. Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, et al. (2010). Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 70, 8264-8269.
35. Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al. (2011). COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474, 403-406.